子长市市场监督管理局 处罚日期 2025年12月30日 子市监处罚〔2025〕61号 浏览：2次 基本信息： 处罚机关 处罚依据 《化妆品监督管理条例》 / 第六十条 / 第五项 变更： 文本信息：该行政处罚决定未上传处罚文书。 处罚种类 没收非法财物,警告,罚款 ...

除了生产端，销售端的线上渠道特性也让监管难度进一步升级。当前化妆品销售越来越以线上渠道为主 阵地，直播等网络销售涉及多个环节主体、隐秘性强，有些环节很难在监管层面被发现。"线上销售的 产品经营地、注册地、发货地、生产地均不相同，主体多元、复杂。直播销售的广告话术、链接产品均 为即时动态更新，监管很难把控。"该负责人表示。 除上述具体难点外，监管资源与任务量存在不匹配的长期矛盾，也是制约监管效能的关键因素。尽管法 规标准体系日趋完善，但如何更科学、高效地实施监管，仍是重大课题。 为破解监管困境，2025年11月，国家药品监督管理局发布了《关于深化化妆品监管改革促进产业高质量 发展的意见》（下称《意见》），该《意见》被业内人士称为"24条"。 12月30日，在第二届丽水市生态美妆产业发展大会上，化妆品行业相关监管部门负责人表示，国内化妆 品行业发展迅速，但受产品安全使用风险突出、线上销售环节不透明，加之生产源头管控薄弱等因素影 响，行业监管仍面临不少现实难度。 "该份文件是在2020年《化妆品监督管理条例》基础上的一次重大革新，融入了我们五年来总结的基本 经验，其中最难的是论证环节"。前述负责人告诉经济观察报，文 ...

转自：云南省药品监督管理局网站 查办结果：蒋某艳等人生产、销售假药的行为违反了《中华人民共和国药品管理法》第九十八条第一款规定，触犯了《中华人民共和国刑法》第一百四十一 条第一款规定，构成生产、销售假药罪。2025年4月，经楚雄州武定县人民法院审理，对5名主犯判决如下：（一）以生产、销售假药罪判处蒋某艳有期徒刑 11年6个月、罚金233万元、附带民事公益诉讼惩罚性赔偿金33.6万元，判处蒋某德有期徒刑10年4个月、罚金135万元、附带民事公益诉讼惩罚性赔偿金18.6 万，判处黄某仙有期徒刑3年缓期5年执行、罚金11万元，判处蒋某刚有期徒刑1年、罚金10万元；（二）以销售假药罪判处范某海有期徒刑4年6个月、罚金 53万元、附带民事公益诉讼惩罚性赔偿金7.77万。 三、个旧市某中医诊所使用劣药案 案情概述：2025年5月14日，个旧市市场监督管理局（以下简称个旧局）根据举报线索，对个旧市某中医诊所（以下简称当事人）药品使用情况进行现场检 查。现场检查发现药品"龟甲胶"19片（批号：2103011，包装规格：14片/板×3板/盒，有效期至：2024-02-29），个旧局现场对上述药品采取了扣押的行政强 制措施，并于 ...

Group 1: Regulatory Developments - The National Medical Products Administration (NMPA) held a meeting to summarize the regulatory achievements of 2025 and discuss key work for 2026, emphasizing the need for comprehensive regulatory reforms in the cosmetics industry [1] - The meeting highlighted that the Chinese cosmetics market is projected to reach a total transaction value of 1,073.82 billion yuan in 2024, indicating continuous market expansion [1] - Despite the growth, the industry faces structural issues, with over 20,000 registered cosmetics companies but low market concentration and a lack of globally influential brands [1] Group 2: Clinical Innovations and Approvals - The first non-injection epinephrine product, Neffy® (优敏速®), has been approved in China for emergency treatment of severe allergic reactions, marking a significant milestone in drug innovation [4] - HaiXiang Pharmaceutical announced the initiation of Phase II clinical trials for NWRD06, a novel nucleic acid drug aimed at preventing liver cancer recurrence, which is the first of its kind targeting the GPC3 marker [5] - Xinhua Medical received registration for two types of medical devices, enhancing its competitiveness in the in vitro diagnostics market [6] Group 3: Financing and Market Expansion - Beijing Ruifeng Biotechnology completed a C-round financing of over 100 million yuan, aimed at expanding its commercial capabilities and enhancing research and development in both human and animal health [8][9] - Humatrix Medical announced the completion of an A+ round financing of over 100 million yuan, which will be used to advance clinical trials for its core product and expand its product pipeline [10] Group 4: Healthcare Insurance and Spending - The National Healthcare Security Administration reported that from January to November 2025, the total income of the basic medical insurance fund reached 2.632 trillion yuan, with total expenditures of 2.110 trillion yuan, indicating stable fund operations [12]

人民财讯12月29日电，12月29日，国家药监局在石家庄召开化妆品监管工作座谈会，总结2025年监管工 作成效，分析当前形势，研究2026年重点工作思路。会议强调，2026年是"十五五"规划开局之年，要深 入贯彻落实党的二十大和二十届历次全会精神，按照国家药监局的统一部署，围绕中心、突出重点，持 续深化全过程监管改革，全方位筑牢安全底线，全链条促进化妆品产业高质量发展。 ...

12月27日，韩束在其官方微博发布回应。承诺韩束旗下所有产品均未添加人表皮生长因子（EGF）成 分。 其表示，近日，关于我司旗下产品"韩束丰盈紧致精华面膜"和"韩束嫩白透亮面膜"添加人表皮生长因子 （EGF）的报道引发了部分消费者的担忧。 （企业官微） 报道发生后，我们已立即启动全面自查与追溯程序。早在2025年11月，上海市药品监督管理局稽查局已 就该产品开展了现场核验与检测，并基于客观公允性进行了双向送检，结果均显示：送检样品中均未添 加人表皮生长因子（EGF）成分。 我们怀着最诚恳的心情，虚心接受媒体的监督与审视，认真倾听每一位消费者的心声。同时我们郑重承 诺，未来，韩束品牌所有在售产品将一如既往严格遵循国家《化妆品监督管理条例》《化妆品安全技术 规范》等法规要求，积极配合监管部门工作 。韩束将始终坚守"脚踏实地、持续精进"的初心，持续优 化产品与服务，不负每一份信任与期待。 ...

Group 1 - The core viewpoint emphasizes the importance of enhancing cosmetic regulation to ensure public safety and effectiveness in monitoring [1] - The Shandong Provincial Drug Administration is implementing a targeted sampling inspection plan for cosmetics in 2025, focusing on children's cosmetics, special cosmetics, and products with high non-compliance rates [1] - The sampling process will cover the entire production and sales chain, with increased inspection efforts in key areas such as trading markets and e-commerce platforms to ensure representativeness and problem orientation [1] Group 2 - A strict "five measures in place" principle will be enforced for non-compliant cosmetics, including product control, source tracing, cause investigation, administrative penalties, and corrective actions [2] - Immediate actions will be taken against confirmed non-compliant products, including orders for removal, suspension, and recall, along with legal investigations into the source of issues [2] - A traceability mechanism for non-compliant products will be established, facilitating collaboration with regulatory bodies in other regions to enhance cross-regional regulatory efforts [2]

Core Viewpoint - The article highlights the severe penalties imposed on Nanjing Sucao Tang Pharmaceutical Co., Ltd. for providing falsified cosmetic registration documents, reflecting a strict regulatory stance in the cosmetics industry against such fraudulent practices [1][2][17]. Group 1: Regulatory Actions - Nanjing Sucao Tang was fined a total of over 2.07 million yuan for submitting fake "test reports" and safety assessment documents for 14 cosmetic products [1][4]. - The penalties included a fine of 2,052,345.63 yuan, confiscation of illegal gains amounting to 24,000 yuan, and the cancellation of product registrations for 14 items [4][18]. - The company is barred from submitting related registration applications for three years, indicating a zero-tolerance policy from regulatory authorities towards registration fraud [2][4]. Group 2: Company Background and Violations - Nanjing Sucao Tang, established in 2016, operates in various sectors including medical beauty and personal care, with brands such as Sucao Tang and Suberal [3][4]. - The company has a history of regulatory violations, having been penalized multiple times in the past three years, indicating systemic compliance issues [6][11]. - The specific violations involved the submission of falsified documents, which contravenes the requirements for the authenticity of registration materials as per the Cosmetics Supervision and Administration Regulations [4][17]. Group 3: Industry Implications - The incident underscores a broader trend in the cosmetics industry towards stricter regulatory enforcement, with increasing penalties for violations becoming a norm [17][21]. - Regulatory measures now encompass financial penalties, qualification penalties, and market bans, reflecting a comprehensive approach to compliance enforcement [18][21]. - The article emphasizes the need for companies to establish robust compliance systems to navigate the increasingly stringent regulatory landscape, as any attempts to circumvent regulations will face severe repercussions [17][21].

Core Insights - The sunscreen market in China is experiencing significant growth, with a wide price range for products, from as low as 0.99 yuan to several hundred yuan, indicating a disparity in quality and production practices [1][3][14] - Many low-priced sunscreens achieve their low costs through questionable practices, such as underdosing active ingredients and mislabeling SPF values, leading to potential consumer safety concerns [4][5][6] - The industry faces challenges with regulatory compliance, as some manufacturers exploit loopholes to produce and market sunscreens without proper certifications [2][8][11] Price Discrepancy - Sunscreens with SPF 50 are available at various price points, with many low-cost options selling over 100,000 units despite their questionable quality [3][4] - The core cost of sunscreen primarily comes from the active ingredients, with some manufacturers offering raw materials at prices as low as 60 yuan per kilogram, significantly impacting the final product cost [3][4] - High-quality sunscreens typically range from 50 to 200 yuan, which accounts for over 50% of the total market value, while cheaper alternatives often compromise on ingredient quality [3][14] Production Practices - Some manufacturers engage in practices such as diluting active ingredients during mass production, which allows them to pass initial quality tests while delivering subpar products to consumers [4][5] - The lack of stringent enforcement of regulations has led to a culture of risk-taking among manufacturers, with some believing they will not be caught during inspections [5][6] Regulatory Environment - The production of sunscreens requires special certifications, which can be costly and time-consuming, leading to practices like "certificate borrowing" where companies use existing certifications for new products [6][8] - Despite recent regulatory efforts to curb these practices, some manufacturers still claim to offer "certificate borrowing" services, indicating ongoing compliance issues within the industry [8][11] Consumer Guidance - Experts suggest that consumers should prioritize brands that maintain control over their production processes and choose products based on their specific skin needs and usage scenarios [16] - The importance of selecting sunscreens with proper certifications is emphasized, as these products are more likely to meet safety and efficacy standards [16]

Group 1 - The core viewpoint is that the children's cosmetics market in China is experiencing rapid growth, with a significant increase in both the number of registered products and market size, driven by improved regulatory frameworks and consumer demand [1][2] - As of June 2025, there are 28,168 registered ordinary children's cosmetics, with 27,219 being domestic and 949 imported, and 427 registered special children's cosmetics, with 406 domestic and 21 imported [1] - The market for children's skincare products is projected to exceed 50 billion yuan by 2025, while the children's color cosmetics market is expected to grow from over 10 billion yuan in 2019 to 24 billion yuan by 2025, reflecting a compound annual growth rate of over 20% [1] Group 2 - The National Medical Products Administration (NMPA) has established specific regulatory requirements for children's cosmetics, emphasizing "safety first, necessary efficacy, and minimal formulation" [2] - The NMPA has introduced a dedicated label, the "Little Golden Shield," to enhance the identification of children's cosmetics, aiding consumers in making informed purchasing decisions [2] - The technical guidelines for children's cosmetics have been refined based on children's physiological characteristics and skin properties, aiming to improve product safety standards [2]